Simultaneously, BofA Securities raised the price target for Annexon to $12.00 from $11.00 while maintaining a Buy rating, expressing optimism about the potential approval of ANX005.

Based on topline data from a trial conducted in Bangladesh and the Philippines, the Brisbane, California-based biotech said ANX005 at a 30 mg/kg dose led to a statistically significant 2.4-fold ...

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License ...